TY  - JOUR
T1  - Current trends and future prospective of human papillomavirus vaccination - Need, impact, and challenges
A1  - Nithya Arigapudi
A1  - Tarun Suvvari
A1  - L Simhachalam Kutikuppala
JF  - Clinical Cancer Investigation Journal
JO  - Clin Cancer Investig J
SN  - 2278-0513
Y1  - 2021
VL  - 10
IS  - 4
DO  - 10.4103/ccij.ccij_189_20
SP  - 186
EP  - 188
N2  - 
Human papillomavirus (HPV) is a group of viruses that commonly produce skin or mucous membrane growths. It is most often transmitted through the sexual route and is a common etiological factor for as many as six types of cancers, but majorly, the cervical cancer; implying the impact of cervical cancer worldwide could be reduced by widespread immunization with the HPV vaccine. The HPV vaccine, in two separate doses, can be given starting from 9 years of age, and is highly recommended for females of (or entering) the sexually active age group; it is considered to be very safe and effective, as reported after 12 years of monitoring and research. Although HPV vaccination is the approved public health intervention to reduce the risk of developing HPV-associated cancers, it is yet to see a large-scale implementation. In this article, we discuss about the vaccine, its benefits, the reasons regarding its unacceptance, and whether it is merely an adjunct preventive measure or a necessary one.

UR  - https://ccij-online.org/article/current-trends-and-future-prospective-of-human-papillomavirus-vaccination---need,-impact,-and-challenges-910
ER  -